


PHARMACEUTICAL 2020



Amphastar Pharmaceuticals Inc. Rank 55 of 358





PHARMACEUTICAL 2020





Amphastar Pharmaceuticals Inc. Rank 55 of 358

The relative strengths and weaknesses of Amphastar Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amphastar Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Amphastar Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 210%, being 173% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	255,241
Cost of Goods Sold	190,434
Intangible Assets	0
Liabilities, Current	90,009
Liabilities, Non-Current	25,748
Other Assets	97,874
Other Compr. Net Income	1,760
Other Expenses	26,553
Other Liabilities	43,686
Other Net Income	60,267
Other Revenues	322,357
Property and Equipment	233,856
Research and Development	68,853
Selling, General and Administrative Expense	50,279

Output Variable	Value in 1000 USD
Assets	586,971
Liabilities	159,443
Expenses	336,119
Revenues	322,357
Stockholders Equity	427,528
Net Income	46,505
Comprehensive Net Income	47,385
Economic Capital Ratio	210%

